Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Ruben A. Mesa et al.|Haematologica|2013Cited by 162
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben A. Mesa, Srđan Verstovšek, Vikas Gupta et al.|Leukemia|2022Cited by 63